Provided By GlobeNewswire
Last update: Aug 28, 2024
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September:
NASDAQ:BOLT (2/21/2025, 8:04:02 PM)
0.488
-0.02 (-4.29%)
Find more stocks in the Stock Screener